What does a positive myeloproliferative neoplasm (MPN) molecular result (e.g., JAK2 V617F, CALR, MPL) indicate and what are the recommended next steps in evaluation and management?

Positive MPN Molecular Results: Diagnostic Confirmation and Next Steps

A positive molecular result for JAK2 V617F, CALR, or MPL mutation confirms clonal myeloproliferation and eliminates consideration of reactive processes, but does NOT by itself establish which specific MPN subtype you are dealing with—you must complete the full WHO diagnostic workup to distinguish between polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). 1, 2

What the Positive Result Means

The presence of these driver mutations provides proof of clonality and rules out reactive causes of elevated blood counts 1. However, these mutations are not specific to any single MPN subtype:

• JAK2 V617F: Found in >90% of PV patients, ~50-60% of ET patients, and ~50% of PMF patients 3
• CALR mutations: Present in ~15-25% of ET and PMF patients who are JAK2-negative 2
• MPL mutations: Found in ~3-5% of ET and PMF patients who are JAK2/CALR-negative 1, 2

Immediate Next Steps: Complete WHO Diagnostic Criteria

You must integrate the molecular result with clinical, laboratory, and bone marrow findings to establish the specific diagnosis 1, 2, 4:

Required Workup Components:

1. Complete Blood Count Analysis:

   • Hemoglobin/hematocrit levels (PV: Hgb >16.5 g/dL men, >16 g/dL women)
   • Platelet count (ET: sustained ≥450 × 10⁹/L)
   • White blood cell count with differential

2. Bone Marrow Biopsy with Special Stains 2:

   • Morphology assessment (hypercellularity, trilineage vs megakaryocytic predominance)
   • Reticulin and trichrome staining to grade fibrosis (MF-0 through MF-3)
   • Megakaryocyte morphology evaluation

3. Additional Laboratory Tests 2:

   • Serum erythropoietin level (low in PV)
   • Lactate dehydrogenase (LDH)
   • Comprehensive metabolic panel with uric acid
   • Iron studies

4. Exclude BCR-ABL1 2:

   • FISH or RT-PCR to rule out chronic myeloid leukemia
   • If positive, this is CML, not an MPN

5. Cytogenetic Analysis 2:

   • Bone marrow karyotype ± FISH
   • Identifies high-risk cytogenetic abnormalities

Subtype-Specific Diagnostic Algorithms

For JAK2 V617F-Positive Patients:

If elevated hemoglobin/hematocrit → Likely PV. Diagnosis requires 1, 4:

• Major criteria: Elevated Hgb/Hct + JAK2 mutation
• Plus one minor criterion: BM hypercellularity with trilineage growth, low serum EPO, or endogenous erythroid colonies

If isolated thrombocytosis → Likely ET. Must meet all 4 criteria 1:

• Sustained platelets ≥450 × 10⁹/L
• BM showing megakaryocytic proliferation without significant granulocytic/erythroid increase
• Not meeting criteria for PV, PMF, CML, or MDS
• JAK2 V617F present

If leukoerythroblastosis, splenomegaly, or anemia → Consider PMF. Requires 1, 2:

• Major: Megakaryocyte proliferation/atypia with fibrosis (or prefibrotic changes) + JAK2 mutation + exclusion of other disorders
• Plus ≥2 minor: Anemia, leukocytosis ≥11 × 10⁹/L, palpable splenomegaly, elevated LDH, leukoerythroblastosis

For CALR or MPL-Positive Patients:

These mutations are only found in ET and PMF, never in PV 2, 4. Use the same diagnostic criteria as above for ET vs PMF distinction, focusing on:

• Degree of bone marrow fibrosis
• Presence of anemia vs thrombocytosis
• Splenomegaly and constitutional symptoms

Risk Stratification After Diagnosis

Once the specific MPN subtype is established, immediately perform risk stratification 3:

For PV and ET:

• High risk: Age >60 years OR prior thrombosis history
• Low risk: Age ≤60 years AND no prior thrombosis
• Assess cardiovascular risk factors

For PMF:

• Use DIPSS-Plus scoring system (preferred) 2:
  • Age >65 years
  • Constitutional symptoms
  • Hemoglobin <10 g/dL
  • Leukocytes >25 × 10⁹/L
  • Circulating blasts ≥1%
  • Platelet count <100 × 10⁹/L
  • Transfusion dependency
  • Unfavorable karyotype
• Risk categories: Low (0), Intermediate-1 (1), Intermediate-2 (2-3), High (≥4)

Additional Molecular Testing Considerations

If JAK2/CALR/MPL are all negative ("triple-negative") 2, 4:

• Test for JAK2 exon 12 mutations (if PV suspected)
• Consider expanded NGS panel for other clonal markers (ASXL1, EZH2, TET2, IDH1/2, SRSF2, SF3B1)
• These additional mutations have prognostic significance and help confirm clonality

Critical Pitfalls to Avoid

1. Do not diagnose MPN based on molecular testing alone—the mutation confirms clonality but WHO criteria require integration with clinical/pathologic features 1

2. Do not assume JAK2 V617F = PV—this mutation is present in all three major MPN subtypes 1

3. Do not skip bone marrow biopsy—it is essential for distinguishing ET from prefibrotic PMF, which have different prognoses 1, 2

4. Do not forget to exclude reactive causes—even with a positive mutation, ensure no secondary causes of thrombocytosis (iron deficiency, inflammation, infection) or erythrocytosis (hypoxia, EPO-secreting tumors) 1

5. Assess symptom burden systematically using MPN-SAF (Symptom Assessment Form) at baseline 2, 5

Management Initiation

Refer to specialized MPN center for all newly diagnosed patients 2. Initial management depends on final diagnosis and risk category:

• High-risk PV: Phlebotomy (target Hct <45%), aspirin 81-100 mg daily, cytoreduction (hydroxyurea or interferon) 3, 5
• High-risk ET: Cytoreduction with hydroxyurea, aspirin 3
• Intermediate-2/High-risk PMF: Evaluate for allogeneic stem cell transplant eligibility; consider ruxolitinib for symptomatic disease 2, 3